Table 1.
Participant Characteristics
| Characteristic | Value |
|---|---|
| Age, years | 57 (43, 64) |
| Female, n (%) | 16 (55) |
| Disease duration, years | 1.2 (0.8, 1.9) |
| HAQ-DI (0–3) | 0.2 (0, 0.7) |
| Patient global (0–10) | 2 (0, 3) |
| Treatments Used (at Time of Study/Ever), n (%) | |
| Methotrexate (oral) | 6 (21)/8 (29) |
| Methotrexate (sc) | 18 (64)/21 (75) |
| Methotrexate (any) | 24 (86)/26 (93) |
| Sulphasalazine | 4 (14)/10 (36) |
| Hydroxychloroquine | 17 (61)/23 (82) |
| Triple therapy | 3 (11)/5 (18) |
| Biologic | 5 (18)/5 (18) |
Note: Values are median (25th, 75th percentiles), unless otherwise stated.